Alpha Cognition (NASDAQ:ACOG) vs. Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Review

Collegium Pharmaceutical (NASDAQ:COLL) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Profitability

This table compares Collegium Pharmaceutical and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	4.68%	85.14%	13.80%
Alpha Cognition	-147.26%	-50.90%	-41.23%

Earnings and Valuation

This table compares Collegium Pharmaceutical and Alpha Cognition”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57 million	0.99	$62.87 million	$1.00	24.95
Alpha Cognition	$10.22 million	18.24	-$20.67 million	($1.10)	-7.78

Collegium Pharmaceutical has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Collegium Pharmaceutical has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Collegium Pharmaceutical and Alpha Cognition, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0	2	7	1	2.90
Alpha Cognition	0	0	5	0	3.00

Collegium Pharmaceutical presently has a consensus target price of $44.88, suggesting a potential upside of 79.86%. Alpha Cognition has a consensus target price of $18.20, suggesting a potential upside of 112.62%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than Collegium Pharmaceutical.

Summary

Collegium Pharmaceutical beats Alpha Cognition on 8 of the 12 factors compared between the two stocks.

About Collegium Pharmaceutical

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

About Alpha Cognition

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.